OX40 (CD134), a key costimulatory molecule in the tumor necrosis factor receptor superfamily, is crucial for enhancing T cell function and driving anti-tumor immunity, making it a significant focus in cancer immunotherapy research.<\/p>\n
OX40 is a transmembrane glycoprotein expressed on activated T cells (peaking 48-72 hours post-activation), but not on naive T cells. Its expression requires both TCR and CD28 signals.<\/p>\n
Upon binding its ligand (OX40L) on antigen-presenting cells, the OX40 trimer recruits TRAFs to its intracellular domain. This activates downstream pathways like NF-\u03baB and PI3K\/AKT.<\/p>\n
This signaling promotes T cell survival by upregulating anti-apoptotic proteins, enhances cytokine secretion, and inhibits the suppressive function of regulatory T cells (Tregs), thereby boosting the immune response.<\/p>\n
Agonist antibodies mimic OX40L to activate the OX40 pathway, enhancing T cell proliferation and effector functions.<\/p>\n
By stimulating effector T cells (Teffs) and inhibiting Tregs, OX40 agonists can convert immunosuppressive \u201ccold\u201d tumors into inflamed \u201chot\u201d tumors.<\/p>\n
Preclinical studies show that combining OX40 agonists with checkpoint inhibitors (like anti-PD-1 or anti-CTLA-4) yields synergistic effects, overcoming resistance to monotherapy and sustaining T cell activity within the tumor microenvironment.<\/p>\n
While early-phase trials show OX40 agonists are safe, objective response rates as monotherapies have been disappointing, likely due to complex tumor microenvironment factors.<\/p>\n
Current research focuses on combination regimens. Early data suggest manageable safety, though efficacy improvements remain a key hurdle.<\/p>\n
To enhance efficacy, researchers are developing bispecific antibodies (e.g., targeting OX40\/CTLA-4 or OX40\/4-1BB) and mRNA-based therapies (e.g., mRNA-2416 encoding OX40L) for localized immune activation.<\/p>\n
OX40 expression on tumor-infiltrating lymphocytes is being explored as a predictive biomarker for patient selection. Despite the challenges, its critical role in costimulation ensures that ongoing innovations in drug design and combination strategies will likely unlock its full potential to benefit cancer patients.<\/p>\n
Read More<\/a>!<\/p>\n Alpha Lifetech, leveraging its profound technical expertise, is committed to providing critical support to global research and industrial clients. We offer high-quality\u00a0Protein Expression and Purification Services<\/a>\u00a0to ensure the correct folding and biological activity of complex transmembrane proteins like OX40. Concurrently, we provide comprehensive, one-stop Custom Antibody Development Solutions, covering antigen design,\u00a0animal immunization<\/a>, and\u00a0screening<\/a>, to empower your innovative research to surmount barriers and deliver tangible clinical benefits to patients sooner.<\/p>\n","protected":false},"excerpt":{"rendered":" OX40 (CD134), a key costimulatory molecule in the tumor necrosis factor receptor superfamily, is crucial for enhancing T cell function and driving anti-tumor immunity, making it a significant focus in cancer immunotherapy research. Structure and Costimulatory Mechanism (i) Expression Pattern OX40 is a transmembrane glycoprotein expressed on activated T cells (peaking 48-72 hours post-activation), but … <\/p>\n","protected":false},"author":1,"featured_media":46,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"slim_seo":{"title":"OX40 Agonists in Cancer Immunotherapy: Mechanisms, Clinical Progress, and Future Directions - Alpha Lifetech","description":"OX40 (CD134), a key costimulatory molecule in the tumor necrosis factor receptor superfamily, is crucial for enhancing T cell function and driving anti-tumor im"},"footnotes":""},"categories":[3],"tags":[],"class_list":["post-22","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-service-post"],"_links":{"self":[{"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/posts\/22","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/comments?post=22"}],"version-history":[{"count":1,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/posts\/22\/revisions"}],"predecessor-version":[{"id":47,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/posts\/22\/revisions\/47"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/media\/46"}],"wp:attachment":[{"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/media?parent=22"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/categories?post=22"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.alphalifetech.com\/index.php\/wp-json\/wp\/v2\/tags?post=22"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}